On August 10, 2023 Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox platform reported an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA) (Press release, Rakuten Medical, AUG 10, 2023, View Source [SID1234634239]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical’s pipeline using its photoimmunotherapy technology platform, Alluminox, in all its MENA markets.
Commenting on the agreement, Mickey Mikitani, Co-CEO of Rakuten Medical, said: "We are already developing Alluminox treatment in several countries and regions, including the United States, Japan, Taiwan, and India, and this agreement further accelerates our global expansion. With Hikma’s strong regional footprint and medical expertise, we expect the Alluminox platform to make significant progress in MENA."
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, added: "This agreement allows us to work with an excellent global partner to strengthen our growing portfolio in oncology and biotechnology. Most importantly, this allows us to bring a potentially transformative technology to cancer patients in MENA, helping to put better health within reach, everyday."
* Rakuten Medical’s therapies based on Alluminox platform are investigational outside of Japan, and not approved in MENA for investigational or commercial use.